Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Molecular Cancer Therapeutics|June 26, 2023
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic TherapiesSabine Zitzmann-Kolbe, Alexander Kristian, Dieter Zopf, et al.
The Journal of Clinical Investigation|January 31, 2017
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancerChiara Berlato, Moddasar N Khan, Tiziana Schioppa, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 2019
Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344Katrine Wickstroem, Urs B Hagemann, Alexander Kristian, et al.
Molecular Pharmaceutics|March 3, 2026
Investigation of Radiolabeled KISS1R Ligands as Promising Tools for Diagnosis and Treatment of Triple-Negative Breast CancerHarun Taş, Martin Schäfer, Aneeba Shuja-Uddin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate CancerStefanie Hammer, Urs B Hagemann, Sabine Zitzmann-Kolbe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive CancersUrs B Hagemann, Christine Ellingsen, Joachim Schuhmacher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2022
89Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted 227Th-Conjugate Therapy in MiceLinda N Broer, Daan G Knapen, Frans V Suurs, et al.
Journal for Immunotherapy of Cancer|October 7, 2021
Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapyPascale Lejeune, Véronique Cruciani, Axel Berg-Larsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate CancerChristoph A Schatz, Sabine Zitzmann-Kolbe, Ingrid Moen, et al.
Pageof 3